According to a new study from The University of Texas MD Anderson Cancer Center, complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials. The procedures were also associated downstream average costs ranging from U.S. $ 6,320 to U.S. $ 56,845.
In the study, published in JAMA Internal Medicine, the researchers show that the findings, reinforce the need to including these risks in the shared decision-making communication between patients and physicians when considering lung cancer screening for high-risk individuals.
The study was supported by the MD Anderson Duncan Family Institute for Cancer Prevention and Risk Assessment funded by the Dan L. Duncan Family, Employees of Halliburton and the Halliburton Foundation, Inc., the University of Florida Health Cancer Center Research Pilot Grant through the Florida Consortium of National Cancer Institute Centers Program, and the National Cancer Institute.
Lung cancer is the second most common cancer in both men and women. In the United States it is the leading cause of cancer deaths.
According to the National Cancer Institute (NCI), about 234,000 people in the U.S. are diagnosed with the disease each year. While most cases are linked to tobacco smoking, a growing number of diagnoses are among non-smokers, especially among women. Most lung cancers are diagnosed after the disease has spread.
“Because most patients with lung cancer are diagnosed at advanced stages, effective early screening strategies for lung cancer are a major public health priority,” explained Ya Chen Tina Shih, Ph.D., professor of Health Services Research and corresponding author on the study.
As a result of the diagnosis in late or advanced stages, the five-year survival rate for lung cancers is just 19%.
In 2011, the National Lung Screening Trial (NLST) demonstrated that lung cancer screening by low-dose computed tomography, known as LDCT, in high-risk individuals achieved approximately a 16 percent reduction in lung cancer mortality. Based on this study, the U.S. Preventive Services Task Force recommends certain current and former smokers ages 55-80 undergo annual LDCT screening for lung cancer.
“When looking at the results of the NLST trial, many have concerns about false positives, which put patients at risk with invasive diagnostic procedures,” Shih noted.
“We felt that downstream complication rates reported in this trial might be underestimated because it was conducted in a well-controlled environment. For screenings conducted in real-world practices, where patients are not subject to clinical trial protocols, we might see even higher complication rates from invasive procedures,” Shih added.
The NLST reported false-positives in nearly one-quarter of participants, meaning the test found cancer when there was none. Reported complication rates for invasive diagnostic procedures, which included cytology/needle biopsies, bronchoscopies or thoracic surgeries, were under 10 percent.
Indirect approach to estimate real-world costs and complications
To investigate complication rates following similar procedures outside of the clinical-trial setting, the researchers analyzed claims data from the MarketScan database between 2008 and 2013. Unfortunately, these data do not indicate if an individual had LDCT screening because the relevant billing code was established in February 2015, so researchers analyzed claims for those who had similar procedures for lung abnormalities as those reported in the NLST.
The study included 174,702 individuals ages 55-77 who had invasive diagnostic procedures and a matched-control group of 169,808 individuals who did not have these procedures to determine a baseline level for complication rates.
“We wanted to understand what the real-world costs and complications might be for diagnostic procedures that typically occur after abnormal results from LDCT screening,” said Shih. “Although we weren’t able to examine a linear path from LDCT screening to invasive diagnostics, the incremental approach applied in our study gives us an estimate of downstream adverse events for these types of procedures in the community setting.”
According to the authors of the study, risks of complications should be shared in patient communications. Among younger individuals (55-64), post-procedural complication rates were 22.2% in the study, compared to just 9.8% in the NLST. For older individuals (65-77), complication rates were 23.8% in the current study and 8.5% in the NLST.
The researchers also performed an analysis of associated downstream costs from post-procedural complications. Managing these complications resulted in higher costs on average than the diagnostic procedures, ranging from $6,320 for minor complications to $56,845 for major complications.
“It’s very important for physicians to include information about possible adverse risks when communicating with their patients considering lung cancer screening,” Shih explained.
“Our findings suggest these complications may be higher than anticipated when implementing lung cancer screening programs outside a clinical-trial setting, and the health care system needs to be ready for that potential issue,” she added.
Shih further pointed out that those having invasive procedures for abnormal findings are a small percentage of all those being screened for lung cancer, likely less than 5%, and lung cancer screening appears to have benefit for those meeting the screening eligibility requirements. Still, it is important to share potential harms and benefits with patients considering lung cancer screening, especially those interested in LDCT screening that do not meet the eligibility criteria.
This study was limited by its retrospective nature and the fact that the most relevant data was unavailable to the researchers at the time of the study. Hence, when data becomes available to show which individuals had invasive procedures subsequent to LDCT screening, the researchers will perform more direct analyses in that group.
Huo J, Xu Y, Sheu T, Volk RJ, Shih YT. Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting. JAMA Intern Med. 2019 Jan 14. doi: 10.1001/jamainternmed.2018.6277. [Pubmed][Article]
Last Editorial Review: January 15, 2019
Featured Image: Doctor reviewing image. Courtesy: © 2010 – 2019 University of Texas MD Anderson Cancer Center. Used with permission.
Copyright © 2010 – 2019 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.